secwatch / observer
8-K filed June 2, 2026, 4:45 PM ET ticker CUE CIK 0001645460
leadership confidence high sentiment neutral materiality 0.60

Cue Biopharma appoints new directors, chief legal officer, and accounting officer; board size reduced

Cue Biopharma, Inc.

item 5.02item 8.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-253709
form_type
8-K
ticker
CUE
cik
0001645460
company_name
Cue Biopharma, Inc.
filed_at
2026-06-02T20:45:51+00:00
discovered_at
2026-06-02T20:47:17.305438+00:00
generated_at
2026-06-02T20:47:30.253845+00:00
sec_items
["5.02", "8.01"]
event_type
leadership
sentiment
neutral
materiality_score
0.6
calibrated_materiality_score
0.6
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-253709
json_url
https://secwatch.observer/filing/0001193125-26-253709.json
markdown_url
https://secwatch.observer/filing/0001193125-26-253709.md
text_url
https://secwatch.observer/filing/0001193125-26-253709.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/d139032d8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Patrick Verheyen

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Departed

Peter Kiener

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Appointed

Daniel Camardo

director
CUE · Cue Biopharma, Inc.
Effective
2026-05-30
Filed
June 2, 2026, 4:45 PM ET
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
Appointed

Viola Meehan

director
CUE · Cue Biopharma, Inc.
Effective
2026-05-30
Filed
June 2, 2026, 4:45 PM ET
On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.
Appointed

Michael Meluzio

Vice President, Principal Accounting Officer
CUE · Cue Biopharma, Inc.
Effective
2026-06-01
Filed
June 2, 2026, 4:45 PM ET
On June 1, 2026, the Board appointed Michael Meluzio as the Company’s Vice President, Principal Accounting Officer, to serve as the Company’s principal accounting officer, effective June 1, 2026.
Appointed

Sumita Ray

Chief Legal & Compliance Officer and Corporate Secretary
CUE · Cue Biopharma, Inc.
Effective
2026-06-01
Filed
June 2, 2026, 4:45 PM ET
On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company’s Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.
Role change

Colin Sandercock

Senior Vice President, Intellectual Property
CUE · Cue Biopharma, Inc.
Effective
2026-06-01
Successor
Sumita Ray
Filed
June 2, 2026, 4:45 PM ET
Mr. Sandercock will continue to serve as the Company’s Senior Vice President, Intellectual Property.
Departed

Jill Broadfoot

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.
Departed

Frank Morich

member of the Board of Directors
CUE · Cue Biopharma, Inc.
Effective
2026-05-29
Filed
June 2, 2026, 4:45 PM ET
On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Source-grounded claims

0315e9ae30

Patrick Verheyen departed as member of the Board of Directors at Cue Biopharma, Inc..

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

2ca23b462b

Peter Kiener departed as member of the Board of Directors at Cue Biopharma, Inc..

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

2e4f2ed2c4

Daniel Camardo was appointed as director at Cue Biopharma, Inc..

On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

573c096941

Viola Meehan was appointed as director at Cue Biopharma, Inc..

On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

7d66bf3983

Michael Meluzio was appointed as Vice President, Principal Accounting Officer at Cue Biopharma, Inc..

On June 1, 2026, the Board appointed Michael Meluzio as the Company’s Vice President, Principal Accounting Officer, to serve as the Company’s principal accounting officer, effective June 1, 2026.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

ab86580cc7

Sumita Ray was appointed as Chief Legal & Compliance Officer and Corporate Secretary at Cue Biopharma, Inc..

On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company’s Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

b26c64a588

Colin Sandercock changed role as Senior Vice President, Intellectual Property at Cue Biopharma, Inc..

Mr. Sandercock will continue to serve as the Company’s Senior Vice President, Intellectual Property.

SEC 8-K Item 5.02 confidence 0.9 SEC evidence

d9e64a264b

Jill Broadfoot departed as member of the Board of Directors at Cue Biopharma, Inc..

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

f71a876bae

Frank Morich departed as member of the Board of Directors at Cue Biopharma, Inc..

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

SEC 8-K Item 5.02 confidence 1.0 SEC evidence

Comparable filings

ONCY

Oncolytics appoints Steve Glover to board, promotes John McAdory to COO

ONCOLYTICS BIOTECH INC June 2, 2026, 9:02 AM ET leadership Items 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 8.01 same event type: leadership similar materiality

This filing

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Comparable filing

appointed John McAdory as Chief Operating Officer of the Company

Filing page SEC filing

GRAL

GRAIL appoints Joshua Ofman as CEO with amended compensation and severance

GRAIL, Inc. June 1, 2026, 4:07 PM ET leadership Items 5.02, 8.01, 9.01

same fact type: executive_change same SEC item: 5.02, 8.01 same event type: leadership similar materiality

This filing

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Comparable filing

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with Dr. Joshua Ofman’s appointment as the Chief Executive Officer of GRAIL, Inc. (the “Company”), on June 1, 2026, the Company’s board of directors (the “Board”) approved an amended and restated offer letter (the “Amended Offer Letter”) and authorized and directed the Company to enter into such Amended Offer Letter with Dr. Ofman, with the Amended Offer Letter effective as of June 1, 2026 (the “Effective Date”).

Filing page SEC filing

LNSR

LENSAR appoints Michael A. Rossi as Interim CFO; annual meeting set for Aug 4, 2026

LENSAR, Inc. May 29, 2026, 4:05 PM ET leadership Items 5.02, 5.08, 8.01

same fact type: executive_change same SEC item: 5.02, 8.01 same event type: leadership similar materiality

This filing

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Comparable filing

On May 25, 2026, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Michael A. Rossi to serve as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of May 29, 2026.

Filing page SEC filing

BTMD

Biote CEO Christensen resigns; CFO Peterson named Interim CEO; Marc Beer Executive Chairman; FY2026 guidance reaffirmed

biote Corp. June 2, 2026, 5:17 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Comparable filing

On June 1, 2026, the Board appointed Marc Beer as Executive Chairman of the Board, effective June 8, 2026.

Filing page SEC filing

NUE

Nucor EVP David Sumoski to retire June 13, 2026; receives $308,851/month for 24 months

NUCOR CORP June 2, 2026, 5:11 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Comparable filing

On May 28, 2026, the Company and Mr. Sumoski entered into a Retirement, Separation, Waiver and Release Agreement (the “Retirement Agreement”) in connection with Mr. Sumoski’s retirement from employment with the Company, effective June 13, 2026.

Filing page SEC filing

BSTT

Zaneta Koplewicz resigns as Co-President and Director of Blackstone Real Estate Income Trust

Blackstone Real Estate Income Trust, Inc. June 2, 2026, 5:08 PM ET leadership Items 5.02

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Comparable filing

On June 2, 2026, Zaneta Koplewicz resigned from Blackstone Real Estate Income Trust, Inc. (the “Company”) as Co-President, Head of Shareholder Relations and as a member of the Company’s Board of Directors (the “Board”), effective June 24, 2026.

Filing page SEC filing

VWAV

VisionWave appoints Einav Eliraz as CFO of subsidiary VisionWave IL; grants 500K share options

VisionWave Holdings, Inc. June 2, 2026, 5:01 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Comparable filing

On June 1, 2026, VisionWave IL Ltd. (“VisionWave IL”), a wholly-owned subsidiary of VisionWave Holdings, Inc. (the “Company”), entered into an Employment Agreement with Mr. Einav Eliraz pursuant to which Mr. Eliraz was appointed Chief Financial Officer (“CFO”) of VisionWave IL, effective June 1, 2026.

Filing page SEC filing

CYCU

Cycurion appoints Ana Garcia as CFO; Alvin McCoy III transitions to strategic advisor

Cycurion, Inc. June 2, 2026, 4:43 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02 same event type: leadership similar materiality

This filing

On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately.

Comparable filing

the Company also announced the appointment of Ana Garcia as its new Chief Financial Officer, effective June 1, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-253709
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.